Application for Genentech’s faricimab accepted by U.S. FDA for treatment of wet AMD and DMO
August 3rd 2021If approved, Genentech’s treatment of faricimab will be the first and only medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.